Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10375901 | 0.93 | SIGMAR1 (0.73) | SIGMAR1 | |
| Carvotroline SCHEMBL350602 | 0.87 | SIGMAR1 (0.88) | SIGMAR1 | |
| Carvotroline SCHEMBL29710918 | 0.87 | SIGMAR1 (0.88) | SIGMAR1 | |
| Carvotroline SCHEMBL123737 | 0.86 | SIGMAR1 (0.86) | SIGMAR1 | |
| SCHEMBL30945720 | 0.84 | SIGMAR1 (0.66) | SIGMAR1 | |
| SCHEMBL10375839 | 0.82 | — | — | |
| SCHEMBL30704375 | 0.81 | ACHE (0.60) | — | |
| SCHEMBL10375702 | 0.81 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL30095886 | 0.81 | ACHE (0.49) | SIGMAR1 | |
| SCHEMBL3254208 | 0.80 | SIGMAR1 (0.67) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433939-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | Alla Chem, LLC. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120071493-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2012-03-22 | — | — | US | disclosed |
| US-20120071493-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2012-03-22 | — | — | US | disclosed |
| US-20110136853-A1 | LIGAND WITH A BROAD SPECTRUM OF PHARMACOLOGICAL ACTIVITY, A PHARMACEUTICAL COMPOSITION, A MEDICINAL AGENT AND A METHOD OF TREATMENT | IVASCHENKO ANDREY ALEXANDROVICH | 2011-06-09 | — | — | US | disclosed |
| US-20110136853-A1 | LIGAND WITH A BROAD SPECTRUM OF PHARMACOLOGICAL ACTIVITY, A PHARMACEUTICAL COMPOSITION, A MEDICINAL AGENT AND A METHOD OF TREATMENT | IVASCHENKO ANDREY ALEXANDROVICH | 2011-06-09 | — | — | US | disclosed |
| EP-2327703-A1 | LIGAND WITH A BROAD SPECTRUM OF PHARMACOLOGICAL ACTIVITY, A PHARMACEUTICAL COMPOSITION, A MEDICINAL AGENT AND A METHOD OF TREATMENT | IVASHCHENKO, Andrey Alexandrovich (RU) | 2011-06-01 | — | — | EP | disclosed |
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ALLA CHEM, LLC (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ALLA CHEM, LLC (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2010134846-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2010-11-25 | — | — | WO | disclosed |
| EP-2236511-A2 | LIGANDS OF ALPHA-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF | Alla Chem, LLC. (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009082268-A2 | LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF | ALLA CHEM, LLC (US) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ADRB3, ADRA2C, ADRB2 | SIGMAR1 71/4885 |
| US-20110136853-A1 | LIGAND WITH A BROAD SPECTRUM OF PHARMACOLOGICAL ACTIVITY, A PHARMACEUTICAL COMPOSITION, A MEDICINAL AGENT AND A METHOD OF TREATMENT | CNR1, TRPV1, TRPM7 | SIGMAR1 253/4885 |
| US-20120071493-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | SIGMAR1, ADRA2C, ADRB2 | SIGMAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.